Reckitt Benckiser : Factsheet (factsheet fy 2025 results)

About this update from Reckitt Benckiser Group Plc

INVESTMENT PROPOSITION "2025 has been a strong year with performance ahead of our expectations. Core Reckitt like-for-like net revenue grew 5.2%, driven by very strong growth in Emerging Markets. Group adjusted operating profit was up 5.3%. Our Fuel for Growth programme is reducing fixed costs, supporting continued investment, capability and efficiency. We delivered another year of EPS growth and £2.3bn of returns to shareholders. Our strategy continues to deliver. We have more work to do but our geographic footprint, portfolio of Powerbrands and focused organisational structure have strengthened our ability to deliver sustainable long-term growth. We look forward with confidence." Kris Licht, Chief Executive Officer STRONG FY 2025 PERFORMANCE Core Reckitt LFL net revenue growth +5.2% Volume: +1.5% Price / mix: +3.7% Core Reckitt Gross profit margin 62.2% Flat Core Reckitt Adjusted operating profit margin 26.7% +90bps Group LFL net revenue growth +5.0% Volume: +0.9% Price / mix: +4.1% Group gross profit margin 60.8% +10bps Group adjusted operating profit margin 24.9% +40bps Group adjusted operating profit growth ¹ +5.3% Adjusted diluted EPS 352.8p +1.1% Refer to adjusted measures presented within the FY 2025 Results announcement. 1. Growth on a constant FX basis. 2025 REFLECTIONS A WORLD-CLASS HEALTH AND HYGIENE COMPANY A year of financial delivery Core Reckitt LFL Net Revenue growth +5.2%, Group +5.0% Benefits of diversified geographic portfolio; Emerging Markets +14.6%, Europe -1.4%, North America +0.2% Group AOP growth of 5.3%, AOP margin 24.9% Core Reckitt AOP margin 26.7% (+90bps vs. FY 24) 51% of Top CMUs in holding or gaining market share Delivering EPS growth despite FX and ETR headwind £2.3bn returned to shareholders, DPS growth of +5.0% Delivering on our strategy Fundamentally reshaping into a more efficient, world-class health and hygiene company Core Reckitt delivering on our medium-term guidance Divestment of Essential Home completed, a significant step in unlocking value Strong progress on FFG, FY 25 fixed costs at 19.4% of NR (-150bps vs. FY 24) Strengthened investment in Powerbrands, FY 25 BEI at 14.6% of NR (+120bps vs. FY 24) Given performance of FFG to date, confidence in fixed costs as % NR below our initial 19% target by end 2027 Platform to deliver long-term growth Investment in innovation driving results, with new category creation and product upgrades Durex category leadership: Intensity launch across markets, upgrades in China Dettol and Lysol extensions driving strong growth in Germ Protection (Activ Botany, Air Sanitizer) Premiumisation strategy in Finish benefiting from innovation enhancements Strong innovation cycle across seasonal and non-seasonal Self Care (Mucinex, Nurofen, VMS) Increased investment in supply chain and R&D: China, North America, digitisation FY 2025 Capex at 4.2% net revenue A PORTFOLIO OF POWERBRANDS DRIVING VALUE CREATION A SIMPLIFIED ORGANISATION EXECUTING WITH EXCELLENCE 2 Product superiority: Innovation & category creation 3 Fuel for Growth delivery 4 Executing with excellence 1 Focused portfolio driving value creation o p e G e r e a r C m d P l o r o h t e e s c u t o i N o H o n r t h A m e r i c a E m e r g i n g M a r s k s e e t s n l S l e e l W f C e t a a r e m i t n I E u r DELIBERATELY CURATED POWERBRAND PORTFOLIO driving of Core Net Revenue SELF CARE GERM PROTECTION HOUSEHOLD CARE INTIMATE WELLNESS SUPERIOR INNOVATION LEADING IN MEDICAL SCIENCE 12 hour COLD & FEVER A BREAKTHROUGH INNOVATION IN THE G2.5BN US COLD & FLU CATEGORY1 The first & only 12hr cold & flu medicine with powerful relief from 7 symptoms >15 years of development, testing and clinical trials Treats fever, headache, body pain, sore throat, cough & chest congestion for 12hrs. 3x longer than most cold medicines 1 st FDA approved NDA (New Drug Application) in the UR category in 15+ years 1. L52wks ending 01/24/26, Nielsen NIQ database. RECENT LAUNCHES WE EXECUTE WITH EXCELLENCE EMERGING MARKETS S e l f h e s u o H I n t i m a t e W e l l n e s s £4.3bn e r a C d l o e t o r NET REVENUE NET REVENUE PROFILE C a r e n o i t c 42% P m r e G of Core Reckitt net revenue PRIORITIES Continuing penetration in mature categories TOP MARKETS MARKET LEADING BRANDS1 Developing nascent categories China India Brazil #1 #1 #1 #1 #1 Scaling up next tier countries EUROPE S e l f C a r e u I W n e t i l l m n a e t s e s £3.4bn e r a C d l o n o m r e NET REVENUE NET REVENUE PROFILE 33% e s o H i t c e t G o r P of Core Reckitt net revenue PRIORITIES Trading up and premiumisation h TOP MARKETS MARKET LEADING BRANDS1 Category expansion through innovation UK Germany Australia #1 #1 #1 #1 #1 Ensuring market competitiveness NORTH AMERICA S e l f C a r e H o u C s a e r h e o l d I W £2.6bn r P m r e G NET REVENUE NET REVENUE PROFILE 25% o i t c e t o n of Core Reckitt net revenue PRIORITIES Expand premium categories TOP MARKETS MARKET LEADING BRANDS1 Customer centric growth US Canada #1 #2 #2 Consistent operational excellence 1. Claims based on information aggregated in part from data supplied by Nielsen through its Retail Measurement Services and in part from data inputs from other suppliers, in each case, for the relevant category, geographic focus and based on FY 2025 (based on branded players only). FUEL FOR GROWTH PROGRAMME DELIVERING AHEAD OF PLAN Simplification Simplify our organisation for scale opportunities + Removal of semi-autonomous GBUs + Reduction in management layers + More unified go-to-market approach + Simplified operating model + SKU rationalisation and process simplification Right size investment Refining scope and integrating capability building into markets + Established unified omnichannel sales and marketing capability + Improved in-store execution through smart tools and frontline automation + Embedding category acceleration pods into Area teams + Functional execution excellence Automation & shared services Reduce cost and improve efficiency + Rolling out end-to-end holistic Global Business Services strategy + Expanding shared service footprint across finance, supply and HR functions Digital & generative AI New opportunities for effectiveness and efficiency + Marketing Gen AI function deployed + Now launched in R&D + Next frontier in procurement and supply, further functions to follow + SAP implementation underway FUEL FOR GROWTH DELIVERING EFFICIENCIES AND INVESTMENT OPTIONALITY 2024 JUL 2024 DEC 2025 DEC 2026 2027 END OF 2027 Target 19% Total fixed cost as % of NR as we exit 2027 Fixed FY 2024 STEADY IMPROVEMENT Target cost base 20.9% 19.4% FY 2025 TOWARDS TARGET Expected higher % of NR due to stranded costs and lower net revenue denominator Expected to fully mitigate stranded costs <19% vs 21.8% in FY 2023 One- off costs1 £161m FY 2024 £179m FY 2025 BALANCE Programme c. £1bn Cost 1. One-off cash costs are restructuring and transformation costs related to the Fuel for Growth Programme and are excluded from the Fixed Cost base. They do not include deal dependent and tax costs. 2026 GUIDANCE ADJUSTED EPS LFL NET REVENUE GROWTH ADJUSTED OPERATING PROFIT MARGIN Fuel for Growth is expected to largely offset the stranded costs associated with the Essential Home divestment Ambition to consistently deliver EPS growth over the medium-term, acknowledging in 2026 the headwind from the divestment of Essential Home Essential Home dilution Tax & Interest FX (current) Underlying AOP growth Vestacy income Share consolidation & buyback CORE RECKITT +4% TO +5% MEAD JOHNSON NUTRITION +LSD% TECHNICAL GUIDANCE £320m - £340m c. 27% c. 4% Adjusted net Adjusted effective Capex as % finance expense tax rate of net revenue FOCUS ON INVESTOR SERIES RECKITT FOCUS ON: DIGITAL SCIENCE Bastien Parizot SVP GBS & AI Enterprise Angela Naef Chief R&D Officer Nigel Richardson Chief Information & Digitisation Officer Date: 14 May 2026 Location: Virtual RECKITT FOCUS ON: NORTH AMERICA Jérôme Lemaire President North America Date: 19 November 2026 Location: New Jersey FURTHER INFORMATION Nick Ashworth Head of Investor Relations +44 (0)7408 812 350 Max Duncombe Investor Relations Associate +44 (0)7491 545 404 Jon Bone Investor Relations Director +44 (0)7408 811 493 Ridwaan Moosa Senior Investor Relations Manager +44 (0)7408 859 639 Caroline Dawson Head of Corporate Access +44 (0)7408 841 478 Theresa Hill Personal Assistant +44 (0)7408 811 763 DISCLAIMER This presentation and any other information discussed at the presentation (collectively, the "presentation") has been prepared by Reckitt Benckiser Group plc (the "Company") solely for your information. The opinions presented herein are based on general information gathered at the time of writing and are subject to change without notice. Information in this presentation sourced from third parties has been obtained from sources believed to be reliable but the Company does not guarantee its accuracy or completeness. The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. This presentation contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as "expects" and "anticipates" and words of similar import. Any statement in this presentation that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside the Company's control. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: the general economic, business, political, geopolitical and social conditions in the key markets in which the Reckitt group of companies (the "Group") operates; the Group's ability to innovate and remain competitive; the Group's investment choices in its portfolio management; the ability of the Group to address existing and emerging environmental and social risks and opportunities; the ability of the Group to manage regulatory, tax and legal matters, including changes thereto; the reliability of the Group's technological infrastructure or that of third parties on which the Group relies including the risk of cyber-attack; interruptions in the Group's supply chain and disruptions to its production facilities; economic volatility including increases in tariffs and the cost of labour, raw materials and commodities; the execution of acquisitions, divestitures and business transformation projects; product safety and quality, and the reputation of the Group's global brands; and the recruitment and retention of key management. These forward-looking statements speak only as of the date of this announcement. Except as required by any applicable law or regulation, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Further details of potential risks and uncertainties affecting the Group are described in the Group's filings with the London Stock Exchange, including the Reckitt Annual Report and Accounts 2024. This presentation does not constitute an offer to sell or issue, or any solicitation of any offer to purchase, subscribe for or otherwise acquire any securities, and nothing contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purposes whatsoever on the information contained in this presentation or on its completeness, accuracy or fairness. The contents of this presentation have not been verified by the Company. en

View stock analysis, news, and events for Reckitt Benckiser Group Plc